产品封面图

4-Phenylbutyric acid

收藏
  • ¥200 - 500
  • MedChemExpress(MCE)已认证
  • 美国
  • HY-A0281
  • 2025年07月13日
    avatar
    品牌商
    14钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 保存条件

      Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.

    • 英文名

      4-PBA; Benzenebutyric acid

    • 库存

      货期:1-2天

    • 供应商

      MedChemExpress LLC

    • CAS号

      1821-12-1

    • 规格

      100 mg/500 mg/5 g

    规格:100 mg产品价格:¥200.0
    规格:500 mg产品价格:¥400.0
    规格:5 g产品价格:¥500.0

    MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。

    4-Phenylbutyric acid

    CAS No. : 1821-12-1

    MCE 国际站:4-Phenylbutyric acid

    产品活性:4-Phenylbutyric acid (4-PBA) 是一种组蛋白去乙酰化酶 (HDAC) 和内质网应激 (ERS) 抑制剂,可用于癌症和感染等疾病的研究。

    研究领域:Cell Cycle/DNA Damage  |  Epigenetics  |  Anti-infection

    作用靶点:HDAC  |  Virus Protease

    In Vitro: 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC, inhibits the growth of NSCLC Cell Lines at 2 mM. Benzenebutyric acid in combination with ciglitizone results in enhanced growth arrest of cancer cells. 4-Phenylbutyric acid (0-5 mM) inhibits ASFV infection in a dose-dependent manner. Benzenebutyric acid also inhibits the ASFV late protein synthesis and disrupts the virus-induced H3K9/K14 hypoacetylation status. Benzenebutyric acid and enrofloxacin act synergistically to abolish ASFV replication. Addition of bafilomycin A1 results in accumulation of LC3II, whereas 4-Phenylbutyric acid substantially reduces this accumulation. LPS decreases the level of p62, whereas Benzenebutyric acid reverses this decrease upon LPS stimulation for 48 h. The percentage of cells with LPS-induced AVOs is increased at 48 h, whereas 4-Phenylbutyric acid significantly reduces this percentage. Specifically, the percentage of cells with AVOs decreases from 61.6% to 53.1% upon Benzenebutyric acid treatment, supporting that 4-Phenylbutyric acid inhibits LPS-induced autophagy. As a positive control for autophagy inhibition, bafilomycin A1 is used. The percentage of cells with LPS-induced AVOs is reduced by bafilomycin A1 treatment. The decreased OC area and fusion index observed after Benzenebutyric acid treatment are not observed with knockdown of ATG7. Inhibition of NF-κB using BAY 11-7082 and JSH23 reduce the LC3 II level upon LPS stimulation and completely abolish the inhibitory effect of Benzenebutyric acid on LPS-induced effects.

    In Vivo: LPS induces significant bone loss and decreases bone mineral density (BMD), bone volume (BV/TV), and trabecular thickness (Tb. Th) compared with PBS alone, whereas trabecular space (Tb. Sp.) is increased. 4-Phenylbutyric acid (4-PBA) attenuates LPS-induced bone loss. Treatment with 4-Phenylbutyric acid increases BMD, BV/TV, and Tb. Th. compared with LPS alone, in addition to decreasing the enlargement of Tb. Sp., but no change is observed when mice are treated with Benzenebutyric acid alone. OC.S/BS as assessed by TRAP staining is also significantly reduced when Benzenebutyric acid is administered to LPS-treated mice. However, OC.N/BS tends to decrease, although not with statistical significance, when mice are treated with Benzenebutyric acid and LPS. These results indicate that the effect of Benzenebutyric acid on OC from LPS-treated mice is to reduce its size rather than number. Consistent with these findings, a marker of bone resorption in vivo, serum CTX-1 which is elevated by LPS treatment is decreased when Benzenebutyric acid administered to LPS-injected mice. However, co-treatment with Benzenebutyric acid do not significantly affect the levels of serum ALP and osteocalcin, 2 markers of bone formation in vivo, compared with LPS alone. Benzenebutyric acid also reduces the LPS-induced rise in serum MCP-1, indicating that Benzenebutyric acid decreases systemic inflammation induced by LPS.

    相关产品:Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Trichostatin A  |  Vorinostat  |  Valproic acid  |  Leupeptin hemisulfate  |  Sulforaphane  |  Panobinostat  |  Entinostat  |  Dynasore  |  Romidepsin  |  Aspirin  |  Brequinar  |  Glycyrrhizic acid  |  Tucidinostat  |  Artesunate  |  RGFP966  |  Belinostat  |  Sodium 4-phenylbutyrate  |  Ricolinostat  |  Ebselen  |  Tubastatin A  |  Plerixafor octahydrochloride  |  TMP195  |  Theophylline  |  Carbamazepine  |  Mocetinostat  |  Santacruzamate A  |  ITSA-1  |  NGI-1  |  TMP269

    热门产品线:重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

    Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

    类药多样性化合物库
    顾客使用MCE产品发表的科研文献
    一站式药筛新体验
    MCE 您身边的生物活性分子大师 | 抑制剂、激动剂、化合物库
    重组蛋白 | 高纯度、高稳定性
    磁珠
    MCE Hotline: 4008203792 | 中国现货 - 全球文献引用 - 高纯度高品质 - 全方位技术支持

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    • 尿刊酸 urocanic acid

      β-咪唑丙烯酸。给予狗大量的组氨酸后可从尿中得到,还有细菌作用于组氨酸也能生成尿刊酸。在哺乳类的肝脏或细菌中作为从组氨酸到谷氨酸的代谢途径的中间体,在组氨酸酶的作用下进行分子内的无氧脱氨基而生成。通常尿刊酸在肝脏酶(尿刊酸酶)的作用下进一步分解转变成谷氨酸。  

    • 胆酸cholic acid

          C24 H40 O5 3α, 7α, 12α三羟基 -5 β胆烷酸,是广泛分布于以人为首的脊椎动物中的最主要的胆汁酸。在胆汁中,以与甘氨酸或牛磺酸结合成甘胆酸( glycocholic acid)或牛磺胆酸的形态存在。  

    • 乳酸 lactic acid

         α -羟基丙酸。 L型(见图)为厌氧糖酵解的最终产物,是由乳酸脱氧酶的作用使丙酮酸还原而生成的。在激烈的肌肉运动时,乳酸在肌肉中积累,其一部分随血液流到肝脏,再合成为葡萄糖(糖的产生)。在乳酸菌的乳酸发酵和大肠杆菌、梭状芽胞杆菌属的混合有机酸发酵过程中也能大量形成乳酸,为酸乳酪( yoghurt)和咸菜的酸味的主要成分。这里因生物种类不同,有时可产生 L型、 D型和外消旋体。在动物和微生物中是作为碳源而被利用的物质之一。  

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥100
    TargetMol中国
    2025年10月26日询价
    询价
    西宝生物科技(上海)股份有限公司
    2025年07月04日询价
    询价
    北京孚博生物科技有限公司
    2025年07月13日询价
    ¥350
    广州威佳科技有限公司
    2025年07月20日询价
    询价
    富士胶片和光(广州)贸易有限公司
    2025年07月11日询价
    4-Phenylbutyric acid
    ¥200 - 500